Why the study?
The benefit and safety of apixaban to reduce stroke risk in morbidly obese patients with nonvalvular AF remain undetermined due to limited clinical data.
Does apixaban 5 mg twice daily prevent thrombotic events similarly in morbidly obese (BMI ≥ 40) compared to non-morbidly obese patients with non-valvular atrial fibrillation?
Does apixaban 5 mg twice daily prevent thrombotic events similarly in morbidly obese (BMI ≥ 40) compared to non-morbidly obese patients with non-valvular atrial fibrillation?
Apixaban demonstrated similar effectiveness and safety for stroke prevention in morbidly obese (BMI ≥ 40) patients with non-valvular atrial fibrillation compared to non-morbidly obese patients.
No takes yet. Share an insight, caveat, or question.
Supports apixaban effectiveness in morbid obesity; hypothesis-generating and requires randomized confirmation.
Sulaiman et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: